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Abstract
Background: Large-scale studies risk generating inaccurate and missing data due to the complexity of data
collection. Technology has the potential to improve data quality by providing operational support to data
collectors. However, this potential is under-explored in community-based trials. The Aspirin in reducing events in
the elderly (ASPREE) trial developed a data suite that was specifically designed to support data collectors: the
ASPREE Web Accessible Relational Database (AWARD). This paper describes AWARD and the impact of system
design on data quality.
Methods: AWARD’s operational requirements, conceptual design, key challenges and design solutions for data
quality are presented. Impact of design features is assessed through comparison of baseline data collected prior to
implementation of key functionality (n = 1000) with data collected post implementation (n = 18,114). Overall data
quality is assessed according to data category.
Results: At baseline, implementation of user-driven functionality reduced staff error (from 0.3% to 0.01%), out-of-
range data entry (from 0.14% to 0.04%) and protocol deviations (from 0.4% to 0.08%). In the longitudinal data set,
which contained more than 39 million data values collected within AWARD, 96.6% of data values were entered
within specified query range or found to be accurate upon querying. The remaining data were missing (3.4%).
Participant non-attendance at scheduled study activity was the most common cause of missing data. Costs
associated with cleaning data in ASPREE were lower than expected compared with reports from other trials.
Conclusions: Clinical trials undertake complex operational activity in order to collect data, but technology rarely
provides sufficient support. We find the AWARD suite provides proof of principle that designing technology to
support data collectors can mitigate known causes of poor data quality and produce higher-quality data. Health
information technology (IT) products that support the conduct of scheduled activity in addition to traditional data
entry will enhance community-based clinical trials. A standardised framework for reporting data quality would aid
comparisons across clinical trials.
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Background
Results from clinical trials often form the backbone of clin-
ical guidelines. Therefore, it is essential that trials produce
high quality data by minimising erroneous and missing data
[1]. Current strategies for improving data quality focus on
trial design, conduct and governance [2, 3], and limiting
data collection to essential items in order to restrict the po-
tential for inaccurate and missing data [2, 4–6]. Hospital-
based trials can limit research data collection by leveraging
existing data within the electronic health record (EHR) [7].
However, community-based trials operate outside the data
infrastructure. For complex, large-scale community-based
trials, data quality hinges upon data collectors accurately
administering questionnaires and conducting assessments
with participants, abstracting data from clinical records
when relevant and where available, and executing processes
to follow up unusual data and event triggers. This is a chal-
lenging remit and carries risks for data quality.
Poor data quality arises for a variety of reasons including
insufficient operational support for data collections [8],
complex data abstraction procedures requiring data col-
lectors to interpret and adhere to definitions [2, 8–11] and
manual calculation of values [12]. While modern data col-
lection systems have been shown to improve data quality
through improved data validation [13], they are only ef-
fective to the extent that they are intuitive and the end-
users can readily work with the system. Indeed, the extent
to which technology can be used efficiently, effectively and
satisfactorily by users has been an important limiting fac-
tor in the update of EHR systems [14, 15]. Poor usability
has been linked to inefficiency, frustration, confusion and
stress for study staff [15, 16], which may negatively impact
data quality. Conversely, improvements in usability have
been shown to improve data quality and reduce errors in
a hospital setting [17, 18]. However, to the knowledge of
the authors no in-depth study of the role and impact of
technology in quality assurance for trials has been con-
ducted in the community.
The ASPirin in Reducing Events in the Elderly (ASPREE)
study was a community-based randomised, double-blinded,
placebo-controlled multi-centre trial (n = 19,114) of daily
100mg enteric-coated aspirin in healthy community-
dwelling older adults in Australia (n = 16,703) and the USA
(n = 2411). ASPREE included in-person data collection at
baseline visits, quarterly phone calls throughout follow up
and an average of five annual data collection visits con-
ducted at community venues, general practice clinics and
clinical trial centres (~ 1990 data values per participant in
total). Data collection included physical and lifestyle mea-
sures, personal and family history, measurement of haemo-
globin, fasting glucose, creatinine, lipid panel and urinary
albumin:creatinine ratio, a cognitive battery, mood and de-
pression questionnaire, physical function measures (gait
speed and grip strength), Katz activities of daily living,
quality of life and clinical endpoint screening (death, de-
mentia, disability, cancer, cardiovascular disease, depression
and major haemorrhage) [19, 20]. All endpoint triggers re-
quired supporting clinical documentation (manually re-
trieved by ASPREE staff from health services) and
subsequent adjudication by a panel of clinical experts. This
activity occurred across 43 study sites and involved more
than 900 office-based and in-field data collectors.
ASPREE required a data collection system that could
support a wide range of activity that was in addition to
direct data entry and included the precise tracking of
staff activity “in the field”, study medication, accuracy of
measurement devices, venues for study visits (e.g. pri-
mary care practices), vehicles (and their availability for
staff activity) and follow up of clinical events. At the
time of study commencement there was no “off the
shelf” commercial or freeware software meeting these re-
quirements. The data collection system used for the
ASPREE pilot study [21] consisted of simple data entry
web forms with limited validation. To support ASPREE,
this system was expanded to support key operational
processes (e.g. participant recruitment, correspondence,
visit scheduling, event detection) in addition to data col-
lection. By shaping the system in consultation with, and
anticipating the needs of, data collectors, it was hypothe-
sised that the improved operational support would pro-
duce higher-quality data. The final result was a
sophisticated, flexible, modular data solution called the
ASPREE Web Accessible Relational Database (AWARD)
suite. In this paper we discuss four known challenges to
data quality challenges that were identified in the litera-
ture and confirmed through consultation with data col-
lectors, and present the design solution for each
challenge implemented in AWARD. The positive impact
of these solutions on data quality is presented through a
comprehensive account of the quality of AWARD longi-
tudinal data.
Method
Developing AWARD system requirements
Key operational requirements identified via a needs as-
sessment included study visit venue (medical practice or
community venue) room booking, participant visit book-
ing, tracking and conduct of 3-monthly retention calls,
tracking of study medication bottles, retention of partici-
pants at risk of withdrawal, communication with primary
care physicians, staff decision and protocol adherence
support, data entry of primary study data, entry of oper-
ational data such as contact details, and maintenance of
confidentiality by providing different levels of access so
that access to identifying information was limited to site
staff. A design solution was implemented for each key
requirement (see Table 1) by systematically upgrading
the ASPREE pilot [21] system that had been developed
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in house between 2002 and 2003. Completion of major
upgrades occurred over 12–15months. During this time
the simple ASPREE pilot web forms were utilised for
data collection. Over the next 3 years additional modules
for general practitioner recruitment and event adjudica-
tion were deployed.
Overview of the AWARD suite
The AWARD suite consisted of four communicating
modules, each with a particular focus and a specific
group of users: AWARD-Data, AWARD-General Practice
(AWARD-GP), AWARD-Adjudicator and AWARD-Ac-
cess Management System (AMS) (Fig. 1). AWARD-Data
Table 1 Operational and data management considerations and solutions
Operational
domain
Key requirements Design solution
Visit booking - Identification of participants to be booked and the visit
required
- Organisation of “due” participants by visit venue
- Computation of visit venue booking time
- Recording and tracking of venue room bookings
- Recording tracking of participants bookings linked with
room bookings
“2 step” solution implemented
- Venue room booking information entered via a single web
page
- Participants’ booking information entered on a nested
web page
Bookings presented in both calendar and list format via the
web application
Conduct of calls - Identification of participants to be contacted
- Mechanism to record call attempts and messages
- Mechanism to record if participants are unavailable for calls
at certain timepoints
Online call tracking implemented
- List of participants due and eligible to receive calls available
via web application




- Tracking of dispensing and retrieval of study medication
bottle
- Mechanism to ensure that the correct medication is provided
to each participant
Online drug log implemented
- Study medication bottle dispensation date and retrieval
date recorded
- Pill count logged
To avoid unnecessary queries caused by transcription errors,
each participant’s unique study medication code prompted
and validated on data entry
Retention - Conduct of scheduled contact at certain timepoints
identified as increasing the risk of participant withdrawal (e.g.
between dementia trigger and completion of additional
cognitive assessment)
- Mechanism required to shift participants at risk of withdrawal
from the regular contact lists to a retention team list
Retention status implemented
- Database “views” utilised to derive a status describing
whether scheduled study contact was appropriate (e.g. not
eligible for phone contact – dementia trigger follow up in
progress)
Status utilised to shift participants from regular contact lists to
retention team lists
Communication - Mechanism for staff to notify PCPs/GPs of abnormal results
- Mechanism for requesting clinical documents from third
parties (e.g. hospitals, specialists and general practitioners)
Curated third party communication pipeline created and
implemented
- Standard document request and abnormal result
notification letters auto-populated with relevant participant
details via web application
- Microsoft Visual Basic for Applications utilised to send
standard letters via fax or email communications
Staff decision
support
- Mechanism to ensure that protocol specified follow up of
endpoints was completed
- Mechanism to ensure protocol specified follow up of
abnormal results was completed
- Mechanism to ensure that only eligible participants
were randomised
Key operational “status” for each study participant or key step
derived and displayed
- Database views utilised to derive a status describing the
operational “next step”’ (e.g. event coded – awaiting
supporting documents; annual visit – overdue etc)
Status displayed on relevant pages on the user interface
Randomisation restrictions implemented
- Automated checks compared entered data against eligibility
criteria
- Randomisation function disabled for ineligible participants
Data entry - Mechanism to alert staff to potentially incorrect data for
review
- Clear process for alerting staff to data queries for resolution
Checks and balances implemented to minimise transcription
errors
- Pre-programmed value ranges, process prompts and proto
col compliance checks, checked at the point of data entry
- Page submission restrictions implemented to check for logic
between values on a page
Staff action list implemented
- Automated checks compared entered data against
acceptable rangesa and produced “action items”
- Staff specific list of action items displayed on “home” page
of AWARD-Data web application
PCP primary care provider, GP general practitioner
aAcceptable ranges were determined by an expert committee based on physiological plausibility
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was the first module deployed (in 2010) for on-site and
in-field data collectors and supported data entry of study
measures and events, participant booking, communica-
tion between study staff and GPs, study medication
tracking and upload of supporting documentation for
events. AWARD-GP was deployed in 2011 to support re-
cruitment staff to register associate investigators (i.e.
GPs) and track recruitment activity [22]. AWARD-Adju-
dicator was deployed in 2013 to support clinical experts
to complete the adjudication workflow for each clinical
event. AWARD-AMS was deployed in 2017 to track and
approve applications to access and analyse ASPREE data.
Technical specifications
Each AWARD module was a discrete web application
linked to a common, secure SQL database located within
an ISO 27001 certified facility at Monash University,
Melbourne, Australia. All data were encrypted in transit
via SSL through the ASPREE web server and Internet
protocol security (IPSec) tunnels to the database cluster.
Access to the AWARD suite was managed by the two
National Coordinating Centres: Melbourne (Australia)
and Minneapolis (USA). These centres were responsible
for confirming the identity of staff members and ensur-
ing staff were trained in Good Clinical Practice and the
appropriate privacy protocols (e.g. Health Insurance
Portability and Accountability Act of 1996). Following
vetting, staff were registered as web application users by
National Coordinating Centre administrators and pro-
vided with system access, which was restricted to data
for their site only. Role-based access control was used to
provide access to additional functionality, and roles were
allocated as required. For example, the AWARD-Adjudi-
cator module was visible only to staff with the endpoint
adjudication role. Permission to assign user roles was
limited to two system administrators. Regional supervi-
sors were responsible for providing technical and oper-
ational training. All user activity was subject to an audit
log.
Key challenge 1 - operational support
The operational needs of ASPREE included support for
traditional data entry and also support for study opera-
tions such as booking study visits for participants and
Fig. 1 Conceptual design and functionality of the ASPREE Web Accessible Relational Database (AWARD) suite. e-forms = electronic versions of
case report or other forms. “Other data library” refers to the library storing unstructured files such as PDF supporting documents, PDF consent
forms and retinal photographs
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communication with third parties. Maintaining a faithful
digital record of the data collected on source documents
at data collection visits was a key operational challenge.
AWARD was designed to assist staff to adhere to the
ASPREE protocol and standard operating procedures by
providing safeguards against transcription errors and
protocol deviations. Each structured data field was sub-
ject to pre-programmed value ranges, process prompts
and protocol compliance checks at the point of data
entry, with the aim of preventing transcription errors in
real time. Staff were alerted to any out-of-range or miss-
ing values when data were saved, and prompted to
double check that these data were correct. Fields relating
to eligibility were subject to additional randomisation re-
strictions meaning that entry of data values that were
outside protocol-based eligibility criteria limits resulted
in inactivation of the randomisation function on the user
interface. Inaccurate manual calculation of variables has
been identified as a source of poor data quality [12].
Thus, wherever possible, staff entered raw data via the
web application (e.g. individual blood pressure readings)
and AWARD was programmed to calculate additional
variables from the raw data (e.g. mean blood pressure).
Integrating multiple data sources to dynamically co-
ordinate study activity is another operational support
challenge. To aid the timely completion of study activity,
AWARD also supported complex operational tasks such
as visit booking. Pre-programmed venue and participant
booking lists were made available to staff in real time via
the web application. Participants ineligible for a visit be-
cause they were deceased, withdrawn or undergoing fol-
low up for the dementia endpoint were automatically
removed from the list when it was generated by
AWARD. Venue booking lists included a calculation of
the time required to complete outstanding activity at the
venue. This calculation included a consideration of the
number of participants requiring a visit, the type of visit
to be conducted for each participant (e.g. a 1-h in-
person visit; or a 15-min medical records search) and, if
the venue was a general practice, the time required to
collect supporting clinical documents. Bookings were
recorded in the web application and logic checks sup-
ported staff to minimise bookings errors (e.g. partici-
pants being followed by medical records could not be
booked for an in-person visit). Staff were able to com-
municate to general practitioners and hospitals using fax
and email buttons.
Key challenge 2 - data abstraction
Data abstraction has been shown to produce poor data
quality in situations where data collectors are expected
to interpret complex criteria. In ASPREE, clinical event
data were manually abstracted from clinical records ob-
tained from primary care providers, hospitals and
specialists that were consequently at risk of data errors.
To minimise the need for interpretation by data collec-
tors, clinical event record forms prompted staff to tran-
scribe key elements that comprised the event definition,
rather than to interpret clinical information and record
outcomes. Logic checks, particularly related to illogical
dates, were implemented to screen for transcription er-
rors. To ensure correctness, primary and secondary end-
points were adjudicated by at least two clinical experts
based on raw transcribed data and PDF copies of clinical
records.
Key challenge 3 - usability
Prior to the development of the AWARD suite, a com-
prehensive understanding of a given participant’s pro-
gression in the study could only be gained by reviewing
existing background data stored across a number of
places. While critical in the accurate completion of cer-
tain study activities, manual integration of this informa-
tion was burdensome, time-consuming and error-prone
as it required traversing several web pages within the
pilot data system. In response, a series of database views
were programmed to retrieve data from multiple “live”
SQL tables and display an appropriate value or instruc-
tion, known operationally as a “status”. Common exam-
ples of such a status include: vital status, retention
status, clinical event status, dementia trigger status, par-
ticipant study file status (i.e. file is with staff, in Compac-
tus storage or archived), document request status (i.e.
document requested from hospital - awaiting response)
etc. These statuses were displayed prominently within
the web application, which enabled viewing of all neces-
sary information on the same page of the user interface,
supporting staff to perform the appropriate action (see
Additional file 1: Figure S1). Statuses also were utilised
to assist in protocol compliance by displaying the oper-
ational “next steps” to be undertaken. For example, if all
necessary documents had been collected for a clinical
event, the event status automatically updated to an in-
struction to send the event for adjudication. This status
was visible on relevant pages of the user interface and
fed into daily reports.
Usability was supported by defining more than 20
user roles that enabled certain content within the
web applications. For example, staff involved in pre-
paring clinical events for adjudication were assigned
the “Endpoint” role. This role enabled staff to view
and enter data collection forms specifically related to
clinical event follow up. Staff without the role could
not view these forms. This ensured that staff only
saw the data entry fields that they were expected to
complete and were not confused by seeing fields that
were not relevant to them.
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Key challenge 4 - cost-effective data querying
In line with good clinical research practice, analytical
data values were subject to quality assurance processes
[6]. All data included in the analysis data set were quer-
ied for missing and out-of-range values. Ranges for indi-
vidual values were determined by the ASPREE
International Data Management Committee (IDMC).
Changes in values between visits were considered out of
range if the change fell outside 3 standard deviations
from the mean change in values between baseline test
values and the next administration of the test (see Add-
itional file 2: Table S1). Automated querying of data for
missing or out of range values produced an “Action List”
of outstanding activity for each staff member. The action
list functioned as a decision support tool, alerting staff
to potential data discrepancies, potential protocol devia-
tions and any protocol-defined clinical follow up that
was required, such as informing the general practitioner/
primary care provider of an abnormal clinical measure
(e.g. high blood pressure). These action items were
prominently displayed for each user on the home page
of each module of the AWARD suite. Actions were re-
solved either by updating the data entered or providing
an explanatory response on the action list (e.g. data
missing due to measurement device error) (see flowchart
in Additional file 3: Figure S2). Responses to action list
queries were monitored and if resolution of a reasonable
number of queries did not identify a transcription error,
query ranges were recalibrated to improve query specifi-
city. The IDMC monitored the resolution of data queries
via the action list. Data that were confirmed to be cor-
rect according to source documentation but considered
to be unlikely or improbable, were reviewed and adjudi-
cated by IDMC. Data adjudicated as implausible (outside
the possible range for humans) were removed and con-
sidered to be missing due to staff error at the time of
data collection.
Longitudinal data set production
At study conclusion AWARD-Data and AWARD-Adjudi-
cator were utilised to prepare a wide-form, longitudinal
data set, following cessation of the randomised interven-
tion on June 12 2017. The resulting data set contained
more than 39 million values (n = 39,108,454). For trans-
parency, the analysis data set contained the full comple-
ment of variables (i.e. for 7 years of follow up) for all
participants. Some data were expected by design to be
blank because the study ended or because the partici-
pant died/withdrew before data collection was sched-
uled, or because of the response to a parent field that
precluded a response (e.g. if the participant was a non-
smoker, the subsequent question about the number of
cigarettes smoked was not asked and hence the data
were blank). Only data that were not expected by design
to be missing were included in the count of missing
data. The initial primary data set for publication was
locked in January 2018.
Data quality analysis methods
The impact of AWARD on data quality was assessed by
comparing baseline data collected from the first 1000
participants, whose data were collected using the pilot
system, with the remaining participants whose baseline
data were collected in AWARD. Descriptive statistics
(numbers and percentage) were used to describe data
completeness and reasons for missing data.
Results
Data flow in ASPREE
AWARD supported data flow between numerous stake-
holders from the time of study commencement in
March 2010 to study closure in June 2017 (Fig. 2).
Impact of AWARD on data quality
A comparison of baseline data quality between the first
1000 participants and remaining participants is pre-
sented in Table 2. The implementation of AWARD re-
duced staff errors as a cause of missing data (0.3% of
entries, reduced to 0.01%), reduced the number of data
values requiring query (0.14% reduced to 0.04%), and re-
duced the proportion of participants randomised in
error (0.4% reduced to 0.08%). Overall, 65% of the first
1000 participants randomised had at least 1 (of approxi-
mately 200) baseline data values missing due to staff
error. After the implementation of AWARD, this re-
duced to 2%.
Longitudinal data quality and completeness at scale
Currently, there is no accepted framework for the pres-
entation of trial data quality. Table 3 details the quality
of data included in the ASPREE longitudinal data set by
data category. Overall, each participant contributed 1990
data values, which included all data that could theoretic-
ally be collected if all participants were followed for 7
years, along with any concomitant medications reported
throughout the study. Data collection was possible for
more than 15.7 million data values, including almost 1
million data values relating to eligibility. The remaining
data values (n = 23,399,596) could not be collected be-
cause data were scheduled for collection after death,
withdrawal of consent, or study closure; or because data
were not possible as a result of the answer provided to a
hierarchical question. Where data collection was pos-
sible, 96.6% of values were entered within range or
found to be correct following the manual resolution of
19,787 data queries. The remaining 3.4% of data were
missing. Overall, 99.9% of eligibility data were complete
(i.e. baseline 3MS, Katz activities of daily living, systolic
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blood pressure, diastolic blood pressure and haemoglo-
bin). Reasons for missing data are shown in Table 4.
Overall, failure to conduct a visit as scheduled was the
most common reason for missing data (2.2% of total
data were missing for this reason) and failure of a third
party to provide requested data was the second most
common reason. The majority of missing data values in
this latter category were laboratory measures that were
not performed at study visits but instead were requested
from pathology testing providers and not ultimately re-
ceived. Participants declining to provide information was
the third most common reason for missing data. The
two most commonly declined variables were demo-
graphic data (3.5% of this category were missing) and
the physical function measures such as the grip strength
and gait speed (4.2% of this category were missing). Staff
and device error accounted for less than 0.1% of missing
data overall and included data values that were consid-
ered to be implausible and removed from the database.
Cost of AWARD
Development of AWARD is estimated to have cost
US$1.1million, based on salary expenditure between
2010 and 2017 for a data manager (responsible for
designing the system) and web programmers (respon-
sible for technical development). This includes hard-
ware and infrastructure costs. Time required to
resolve an action item was calculated based on the
number of queries a single staff member was able to
resolve in an hour. Action item resolution took an
average of 4–6 min at an estimated cost of US$8–10
per query.
Discussion
The impact of technology on research data quality in
clinical trials is poorly understood. Developed to support
ASPREE, the AWARD suite is a custom data system that
harnessed simple technology to provide innovative func-
tionality to support data collectors to undertake complex
Fig. 2 Data flow between stakeholders in the ASPREE clinical trial
Table 2 Data quality comparison, prior and post system upgrade to ASPREE Web Accessible Relational Database (AWARD)
Prior to AWARD With AWARD
Number of participants 1000 18,114
Number of fields collected at baseline 206 220
Baseline data missing due to staff error 646 (0.3%) 351 (0.01%)
Baseline data requiring querying 278 (0.14%) 1469 (0.04%)
Protocol deviations 4 (0.4%) 15 (0.08%)
Proportion of participants with at least 1 missing field due to staff error 65% 2%
Results are presented as number or number (percentage)
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study activities. To achieve study goals, ASPREE re-
quired a complex data flow between stakeholders that
produced a small health-data ecosystem (see Fig. 2).
Conduct of this large study and navigation of such a
complex data flow was only made possible by the
AWARD suite.
Data quality and completeness
The functionality of AWARD, which was specifically de-
signed to produce high-quality data, supported ASPREE
to achieve 96.6% data completeness and accuracy, with
the remaining data being missing. In clinical trials, some
missing data is inevitable due to participant availability









to be correct on querying






number (% of total) number number
Participant demographics 824,947 80 795,984 (96.5%) 0 0 704,173
Clinical informatione 2,413,294 227 2,358,542 (97.7%) 0 14 1,925,584
Pathology 959,347 88 842,136 (87.8%) 0 5 722,685
Medications 939,684 31d 937,256 (99.7%) 0 0 72,444
Family history 293,929 37 286,982 (97.6%) 0 0 413,289
Cognitive measures 2,737,448 590 2,689,837 (98.3%) 0 0 8,539,812
Physical function 509,858 73 488,648 (95.8%) 0 0 885,464
Mood, function and quality of life 6,317,845 749 6,070,867 (96.1%) 0 0 7,998,541
Endpoints 146,243 46 146,243 (100%) 0 0 733,001
Study medication 97,004 8 97,004 (100%) 0 0 55,908
Visit conduct 469,259 61 456,539 (97.3%) 0 0 696,695
TOTAL 15,708,858 1990 15,170,038 (96.6%) 0 19 23,399,596
aIncludes all data values scheduled for collection between randomisation, death, withdrawal of consent, or study closure. Excludes fields that were not active at
the time of data collection, and fields that were not applicable due to a response to a hierarchical question
bAll values queried for missing and out-of-range data
cIncludes all data values scheduled for collection after death, withdrawal on consent or study closure. Also includes fields that were not active at the time of data
collection, and fields that were not applicable due to a response to a hierarchical question
dPlus concomitant medication. The number of medications reported varied for each participant
eIncludes past medical history, past cancer screening, and physical examination measures such as blood pressure, heart rate, height, weight and
abdominal circumference
Table 4 ASPREE longitudinal data completeness






(% of total potential values in category)
Visit not conducted Third party Participant declined Staff/device error Other reasons
Participant demographics 28,963 (3.5%) 1.5% 0% 2.1% < 0.1% 0%
Clinical information 54,738 (2.3%) 1.5% 0% 0.3% < 0.1% 0.4%
Pathology 117,206 (12.2%) 0% 10.2% 0% 0% 2.0%
Medications 2428 (0.3%) 0% 0% 0.1% < 0.1% 0.1%
Family history 6947 (2.4%) 2.0% 0% 0.2% 0.1% 0%
Cognitive measures 47,611 (1.7%) 1.5% 0% 0.3% < 0.1% < 0.1%
Physical function 21,210 (4.2%) 2.6% 0% 1.5% < 0.1% 0%
Mood, function and quality of life 246,978 (3.9%) 3.6% 0% 0.3% 0.1% < 0.1%
Endpoints 0 (0%) 0% 0% 0% 0% 0%
Study medication 0 (0%) 0% 0% 0% 0% 0%
Visit conduct 12,720 (2.7%) 2.7% 0% 0% 0% 0%
TOTAL 538,801 (3.4%) 2.2% 0.6% 0.4% < 0.1% 0.2%
aExcludes fields that were not active at the time of data collection; fields that were not applicable due to a response to a hierarchical question
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at the time when data is scheduled for collection or be-
cause of unavoidable participant dropout. Within the
published literature, 10% missing or incorrect data is the
threshold for poor data quality [6, 10, 23, 24]. ASPREE
data quality is well above this acceptability threshold but
further assessment of data is challenging for a number
of reasons. First, data quality should ideally be compared
with other similar studies, but the published literature
on data quality from other, aspirin trials is limited.
While most studies report the number of participants
lost to follow up, the impact of this dropout on data
completeness and quality is not described [25–28]. The
investigators of the British Doctors Aspirin Trial state
that mortality and morbidity data were considered “vir-
tually complete” [29], but there is insufficient detail to
enable comparison with ASPREE. Fowkes et al. describe
the data management process for the Aspirin for asymp-
tomatic atherosclerosis trial, such as double data entry
into an Access database, but details of resultant data
quality are not provided and hence comparative assess-
ment is not possible [30]. Second, while data quality is
universally recognised as important in health research,
literature published to date has focussed on processes
and practices to produce data quality rather than the
assessment of data quality following study closure [2, 8,
12]. Thus, there is no accepted framework for reporting
or assessing data quality. Given these limitations,
ASPREE data quality can only be assessed in the context
of the goals of the AWARD suite. AWARD was specific-
ally designed to mitigate known contributors to poor
data quality by supporting operational activity, minimis-
ing data abstraction, calculating additional variables and
assisting usability. The AWARD suite supported ASPREE
to adhere to protocol criteria (protocol deviations, n =
19), resolve data queries and limit missing data to well
below the acceptable threshold of 10%. Consequently,
we consider ASPREE data to be of high quality. Com-
parison of baseline data quality between the first 1000
participants whose data were collected prior to imple-
mentation of AWARD demonstrated that AWARD
reduced staff error resulting in missing data, reduced the
number of out-of-range data entered and reduced proto-
col deviations. Some of this improvement could be at-
tributed to the increasing familiarity of the staff with the
study procedures, however, this is unlikely to be the
major contributing reason since staff turnover was high
(~ 900 users within a 7-year period) with new staff being
inducted and trained throughout the study. Conse-
quently, we consider the design of AWARD to be instru-
mental in the overall data quality of ASPREE.
Importance of operational support
Many functions of AWARD were designed to support
operational activity such as visit bookings. Despite this,
failure to complete visits as scheduled was the most
common reason for missing data, accounting for 65% of
all the missing data. While AWARD design features for
data entry, data abstraction and staff decision support
were informed by published literature, operational sup-
port functionality in AWARD was designed in house
without peer-reviewed guidance. Further research and
innovation regarding successful methods for supporting
study operations may improve operational performance
and limit missing in future trials.
Cost effectiveness
Despite improvements associated with electronic data
collection [13], data cleaning is still considered to be an
expensive process. It is generally anticipated that clinical
trials generate 2–3 data queries per electronic data cap-
ture form and that each query costs US$100 to resolve
[6]. According to these figures, ASPREE would have
been expected to produce between 2.6 and 4 million
data queries, at a massive cost to the study. Due to the
checks and balances included in AWARD by design, only
19,787 values required manual checking against the
source documentation, over the course of the entire
study (0.1% of all potential values). Fine tuning of the
range for change over time queries could have further
reduced this number. This was considerably fewer than
expected, significantly reducing the cost of data cleaning.
Implementation of the action list system allowed staff to
resolve data queries within 4–6 min or $US8–10, a cost
saving reduction compared with the standard US$100
cost per query. This was only possible because of the
underlying data entry, operational infrastructure and
functionality of AWARD, which took time and signifi-
cant funds to develop. While the development cost of
AWARD was low in comparison to the cost of the study
as a whole (~ 2% of grant award), the authors recognise
that development of a custom $1.1 million system is be-
yond the scope of many clinical trials and more technol-
ogy solutions are now available to clinical trialists, both
commercial and freeware. However, commercial options
can also be prohibitively expensive and geared towards
billing support more so than operational activity sup-
port. Freeware options are capable of meeting a fair por-
tion of study needs but often lack comprehensive
functionality. Thus, trialists relying on freeware options
must link multiple products in order to construct a
more complete solution, which has its own drawbacks.
Furthermore, in a recent review of clinical trial technol-
ogy, none of 19 systems examined completely supported
the data management needs of clinical trials [31]. We
suggest that the AWARD suite provides proof of
principle that user-centred design can produce high-
quality data by supporting operational activities. Future
clinical trials using commercial or freeware clinical trial
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data systems should also consider whether similar data
collection support features to those described here can
be implemented or developed within their systems.
Strengths, limitations and novelty of AWARD
Strengths
Key strengths of AWARD included user-driven system
design, detailed data quality annotation and custom de-
sign. Together, these features enabled AWARD to sup-
port the entire lifecycle of the ASPREE project by
providing operational support functionality in additional
to carefully controlled data entry.
Limitations
As a custom system, AWARD has limitations. Develop-
ment of AWARD required the engagement of web pro-
grammers to hard-code functionality. At times this
created a bottleneck that meant that rapid implementa-
tion of new functionality was not possible. A system de-
signer with expertise in both medicine and technology
was required to consult with data collectors and design
usable functionality. Availability of this expertise was a
limitation. Additionally, while informal feedback on us-
ability was sought from staff, we did not collect formal
technology usability assessment data.
Novelty
The fact that AWARD successfully serviced the oper-
ational complexities of ASPREE is in itself novel given
that many other systems cannot provide for the
complete needs of a clinical trial [31]. Achieving this
functionality was made possible by the novel design
methodology that focussed on supporting data collec-
tors. The detailed data quality reporting capability of
AWARD enabled demonstration that this design frame-
work did indeed produce higher-quality data.
Conclusion
The AWARD suite is a system that was custom built to
meet the needs of ASPREE’s data ecosystem. AWARD
provides proof of principle that designing technology to
support data collectors can mitigate known causes of
poor data quality; produce higher-quality data and facili-
tate highly detailed reporting. Pre-data collection activ-
ities (e.g. visit booking) are a key area for improvement
in the technical support of clinical trials. Health IT prod-
ucts whether they be commercial, freeware or custom
(such as AWARD) supporting the conduct of operational
activity in addition to traditional data entry will be of en-
hanced use to community-based clinical trials. A stan-
dardised framework for reporting data quality would aid
comparison of data quality across trials.
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